HighTower Advisors’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

HighTower Advisors’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,688	Closed	-$283K	–	3802
2023 Q1	$283K	Hold	27,688	–	–	﹤0.01%	2503
2022 Q4	$278K	Sell	27,688 -387,700	-93%	-$3.86M	﹤0.01%	2524
2022 Q3	$4.09M	Sell	415,388 -72,000	-15%	-$706K	0.01%	883
2022 Q2	$4.75M	Sell	487,388 -2,400	-0.5%	-$23.4K	0.01%	845
2022 Q1	$4.77M	Sell	489,788 -90,350	-16%	-$877K	0.01%	914
2021 Q4	$5.61M	Sell	580,138 -11,150	-2%	-$109K	0.01%	850
2021 Q3	$5.71M	Buy	+591,288	New	+$5.77M	0.02%	764

HighTower Advisors's ORIA Position: Q2 2023 in Review

HighTower Advisors sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 27,688 shares — an estimated $283K sold.

HighTower Advisors first reported a position in ORIA in Q3 2021 and held it in 7 quarters. The position peaked at $5.71M in Q3 2021. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

HighTower Advisors reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 27,688 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $283K.
HighTower Advisors first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 7 quarters.
HighTower Advisors's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $5.71M in Q3 2021.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.